User:Philcapawiki/sandbox

Company Summary

Capa Valve Ltd was founded in 2010 and currently has two directors and shareholders, Mr Kevin Abbott (Managing Director) and Dr Phil Green (Technical Director). In 2021 Capa Valve appointed an experienced medical consultant, Dr Dale Charlton, as Chief Scientific Officer. The company has developed and patented a variety of valve systems suitable for installation into any size standard medical syringe to enable the sequential dispensing of two liquids or to reconstitute a diluent and a powder, a lyophilised cake or a second liquid extremely efficiently.

Company History

The Capa Valve technology was first developed and patented in 2012 as a technology transfer from a bespoke piece of heating system maintenance equipment developed by Kevin Abbott. The novel valve arrangement if miniaturised would find application in medical syringes for dual stage sequential dispense of two separate liquids which was achieved in association with a UK based University. In 2021 Capa Valve further developed the technology in response to the growing application of freeze-dried (lyophilised) drugs and the consequential need for a convenient low-risk, low-cost solution for the reconstitution of lyophilised drugs. In 2022 Capa Valve added to its technology portfolio by addressing this ever-increasing need for such a drug delivery system by introducing two simple parts which can be sized and installed in any standard syringe (glass or polymer) at an estimated cost of around 10 cents. In 2024 an additional patent was filed for using the valve to provide an auto-disable function for a medical syringe. This system can reconstitute a diluent and a powder, a lyophilised cake or a second liquid extremely efficiently using a standard syringe prefilled with the desired drug combination. This prefilled solution addresses many risks associated with current practices for reconstitution such as drug to diluent ratio, correct patient dosage, contamination risks associated with separate drug and diluent packaging and speed of reconstitution and IV administration in emergency situations. These many advantages are afforded at significantly lower cost than current standard practices for drug reconstitution and delivery as well in comparison to other emerging prefilled technologies striving to solve these drug delivery challenges.